联环药业：目前公司在手6个创新药研发项目

Core Viewpoint - The company emphasizes innovation in its research and development strategy, focusing on innovative drugs, improved new drugs, and generic drugs with technical barriers, while gradually reducing investment in ordinary generic drugs [1] Group 1: R&D Focus - The company has six ongoing innovative drug R&D projects, with the core project LH-1801 (SGLT-2 inhibitor) currently in the Ⅲ phase clinical trial, expected to unblind in Q1 2026 [1] - LH-1801 demonstrates differentiated advantages in controlling glycosylated hemoglobin and offers benefits for heart failure and kidney protection, indicating a broad future market potential [1] - The company is also developing LH-1802 for acute myeloid leukemia, which is in clinical trial stages, and LH-1901 for chronic obstructive pulmonary disease, which has initiated phase I clinical trials [1] Group 2: Collaborations and Achievements - The company collaborates with renowned research institutions and universities, including the Shanghai Institute of Pharmaceutical Industry, China Pharmaceutical University, and Zhejiang University, through its academician and doctoral workstations [1] - As of 2025, the company has obtained 13 production approvals and 2 clinical approvals, being one of the two companies to pass the consistency evaluation for methanesulfonic acid phenylephrine injection (1ml: 10mg) [1] - The company is one of three manufacturers in China for the market of benazepril potassium tablets and the first nationwide company to pass the consistency evaluation for hydrochloride quetiapine tablets [1]